Le guselkumab offre une efficacité durable, spécifique à un domaine et globale, selon des indices composites, chez les patients atteints de rhumatisme psoriasique actif
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac375
This analysis found that patients with active PsA who receive treatment with guselkumab can achieve robust and sustained low disease activity or remission. In reaching this conclusion investigators sought to evaluate the efficacy of guselkumab for the treatment of active PsA through the use of composite indices.